Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01117025 · ClinicalTrials.gov registry record · Phase 2
Combined Treatment of Resistant Hypertension and Atrial Fibrillation
A Phase 2 study, sponsored by Meshalkin Research Institute of Pathology of Circulation.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT01117025: Completed Phase 2 study, sponsored by Meshalkin Research Institute of Pathology of Circulation.
NCT01117025 is a Phase 2 study that has completed, run by Meshalkin Research Institute of Pathology of Circulation. The registered enrollment target is 26 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01117025, a Phase 2 study, has completed, sponsored by Meshalkin Research Institute of Pathology of Circulation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is the comparative evaluation of systolic blood pressure (SBP) lowering, atrial fibrillation (AF) recurrence and clinical data in patients with paroxysmal/persistent AF and resistant hypertension, undergoing AF ablation alone or combined with percutaneous renal denervation.
Interventions
- PROCEDURE Circumferential PV isolation
- PROCEDURE Circumferential PVI+renal denervation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
What the finished NCT01117025 record still lists
NCT01117025 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Circumferential PV isolation is the first listed.
NCT01117025 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01117025 about?
NCT01117025 is a clinical study titled "Combined Treatment of Resistant Hypertension and Atrial Fibrillation". The purpose of this study is the comparative evaluation of systolic blood pressure (SBP) lowering, atrial fibrillation (AF) recurrence and clinical data in patients with paroxysmal/persistent AF and resistant hypertension, undergoing AF ablation alone or combined with percutaneous renal denervation.
What is the current status of trial NCT01117025?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2010-04. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01117025?
The interventions under investigation include: Circumferential PV isolation (PROCEDURE), Circumferential PVI+renal denervation (PROCEDURE).
Who is sponsoring clinical trial NCT01117025?
This trial is sponsored by Meshalkin Research Institute of Pathology of Circulation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01117025's enrollment target sits among peer trials
26 1708th of 2000 higher than 282 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia